Y. Bang

发表

High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer

Jae Hyun Kim, S. Lee, S. Im, 2008, British Journal of Cancer.

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

H. Lee, H. Lee, H. Yang, 2012, British Journal of Cancer.

Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?

Jin‐Young Jang, Y. Bang, S. Im, 2016, Clinical and Translational Oncology.

Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas.

K. Choe, H. Lee, W. Kim, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic relevance of lymph node status for patients with ampullary adenocarcinoma after radical resection followed by adjuvant treatment.

Jin‐Young Jang, Y. Bang, Kyubo Kim, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy

Seung-Yong Jeong, Y. Bang, N. Cho, 2013, British Journal of Cancer.

Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study

S. Shah, S. Stein, C. Fuchs, 2021, ESMO open.

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival

S. Im, K. Lee, N. Kim, 2009, British Journal of Cancer.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, B. Solomon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

G. Giaccone, P. Moore, R. Lechleider, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment

A. Blackler, C. Ock, S. Thyparambil, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer

S. Im, Tae-You Kim, T. Kim, 2014, Oncogene.

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

H. Grabsch, S. Im, C. Womack, 2014, British Journal of Cancer.

DNA hypermethylation in gastric cancer

G. Kang, T. Kim, Y. Bang, 2004, Alimentary pharmacology & therapeutics.

International models of investigator-initiated trials: implications for Japan.

E. Trimble, J. Ledermann, K. Kurokawa, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

Y. Bang, Keun-Wook Lee, D. Oh, 2013, Investigational New Drugs.

A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.

Y. Bang, Y. Kim, J. Kim, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Metaplastic Breast Carcinoma: Clinicopathologic Features and Prognostic Value of Triple Negativity

Tae-You Kim, S. Im, I. Park, 2009 .

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

Y. Bang, S. Im, D. Oh, 2009, British Journal of Cancer.

Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study

S. Shah, E. Van Cutsem, J. Tabernero, 2019, Annals of Oncology.

Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives

Y. Bang, Dong-Wan Kim, D. Heo, 2008, British Journal of Cancer.

Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy

J. Kim, S. Im, D. Oh, 2008 .

Antibiotic use during the last days of life in cancer patients.

Y. Bang, J. Kim, Dong-Wan Kim, 2006, European journal of cancer care.

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.

C. Fuchs, E. Van Cutsem, M. Mandalà, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

C. Fuchs, M. Mandalà, C. Shih, 2020 .

The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer.

Hyunna Lee, S. Im, D. Oh, 2010 .

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

E. Van Cutsem, M. Alsina, M. Lichinitser, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of MDR1/ABCB1 single nucleotide polymorphism (SNP) as a prognostic factor for breast cancer patients receiving docetaxel + doxorubicin neoadjuvant chemotherapy

B. Keam, S. Im, D. Oh, 2008 .

HER2 positivity in advanced gastric cancer is comparable to breast cancer

F. Lordick, A. Sawaki, Sook Ryun Park, 2007 .

S. Shah, S. Stein, E. Van Cutsem, 2019, Annals of Oncology.

O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma

N. Sugimoto, D. Sakai, M. Ryu, 2021, Annals of Oncology.